Branded Legacy, Inc. Expands into Biotech and Medical Devices with Acquisition of Bio Legacy Evaluative Group

Branded Legacy, Inc. (OTC: BLEG), a company known for its diversified holdings in the health and wellness sector, has officially expanded its portfolio by acquiring Bio Legacy Evaluative Group. This strategic move, finalized on July 31, 2025, was executed through an all-stock transaction valued at $1.5 million in Preferred D shares. The acquisition signifies Branded Legacy's ambitious foray into the biotech and medical devices industry, aiming to tackle pressing global health issues such as the addiction epidemic and inefficiencies in vaccine distribution.

Under the leadership of CEO Amin Janmohamed, Bio Legacy Evaluative Group brings to the table a patented all-in-one intranasal naloxone device. This innovation is poised to tap into a market expected to surge from $371 million in 2022 to over $1.16 billion by 2032. Additionally, Bio Legacy's technology for the nasal delivery of vaccines and cold-chain therapies presents a promising avenue for enhancing vaccine accessibility and efficacy. The acquisition terms include performance-based conversion milestones, a two-year lock-up period, and a commitment to invest $1 million in research and development following the company's uplisting to OTCQB.

This acquisition not only diversifies Branded Legacy's business model but also aligns with its mission to innovate within the health and wellness sector. By integrating Bio Legacy's cutting-edge technologies, Branded Legacy is well-positioned to make significant contributions to solving some of the most challenging health crises facing the world today. For more details on this transformative acquisition, visit https://ibn.fm/U7eSy.